Cancer nanomedicines: oversold or underappreciated?

Roy van der Meel*, Twan Lammers, Wim E. Hennink

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

68 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalExpert opinion on drug delivery
Issue number1
Publication statusPublished - 2 Jan 2017


  • Cancer nanomedicines
  • Clinical translation
  • Clinical trials
  • Combination treatment
  • Drug delivery
  • Drug targeting
  • EPR effect
  • Triggered release

Cite this